Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason G Kettle

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Bioorganic & Medicinal Chemistry Letters|January 10, 2008
Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitorsRichard Ducray, Peter Ballard, Bernard C Barlaam, et al.
ACS Medicinal Chemistry Letters|May 15, 2024
Vinylpyridine as a Tunable Covalent Warhead Targeting C797 in EGFRNils Pemberton, Nina Compagne, Argyrides Argyrou, et al.
Angewandte Chemie (International Ed. in English)|October 18, 2024
Site-Specific Quadruple-Functionalised AntibodiesToby Journeaux, Michael B Geeson, Thomas V Murray, et al.
Toxicology Research|May 27, 2025
Use of new approach methodology for hepatic safety assessment of covalent inhibitor drug candidatesSara Amberntsson, Alison J Foster, Bhavik Chouhan, et al.
Bioorganic & Medicinal Chemistry Letters|March 29, 2011
Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol seriesBernard Barlaam, Richard Ducray, Christine Lambert-van der Brempt, et al.
Bioorganic & Medicinal Chemistry Letters|April 25, 2008
Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidinesCatherine Bardelle, Darren Cross, Sara Davenport, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2005
5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinasePeter Ballard, Robert H Bradbury, Laurent F A Hennequin, et al.
Bioorganic & Medicinal Chemistry Letters|October 15, 2008
Inhibitors of the tyrosine kinase EphB4. Part 2: structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidinesCatherine Bardelle, Tanya Coleman, Darren Cross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GISTVenkatesh Pilla Reddy, Rana Anjum, Michael Grondine, et al.
Bioorganic & Medicinal Chemistry Letters|June 30, 2006
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokineticsPeter Ballard, Robert H Bradbury, Craig S Harris, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry Letters|January 10, 2008
Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitorsRichard Ducray, Peter Ballard, Bernard C Barlaam, et al.
ACS Medicinal Chemistry Letters|May 15, 2024
Vinylpyridine as a Tunable Covalent Warhead Targeting C797 in EGFRNils Pemberton, Nina Compagne, Argyrides Argyrou, et al.
Angewandte Chemie (International Ed. in English)|October 18, 2024
Site-Specific Quadruple-Functionalised AntibodiesToby Journeaux, Michael B Geeson, Thomas V Murray, et al.
Toxicology Research|May 27, 2025
Use of new approach methodology for hepatic safety assessment of covalent inhibitor drug candidatesSara Amberntsson, Alison J Foster, Bhavik Chouhan, et al.
Bioorganic & Medicinal Chemistry Letters|March 29, 2011
Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol seriesBernard Barlaam, Richard Ducray, Christine Lambert-van der Brempt, et al.
Bioorganic & Medicinal Chemistry Letters|April 25, 2008
Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidinesCatherine Bardelle, Darren Cross, Sara Davenport, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2005
5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinasePeter Ballard, Robert H Bradbury, Laurent F A Hennequin, et al.
Bioorganic & Medicinal Chemistry Letters|October 15, 2008
Inhibitors of the tyrosine kinase EphB4. Part 2: structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidinesCatherine Bardelle, Tanya Coleman, Darren Cross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GISTVenkatesh Pilla Reddy, Rana Anjum, Michael Grondine, et al.
Bioorganic & Medicinal Chemistry Letters|June 30, 2006
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokineticsPeter Ballard, Robert H Bradbury, Craig S Harris, et al.
Pageof 6